Expression of indoleamine 2, 3-dioxygenase in leukemic cells indicates an unfavorable prognosis in acute myeloid leukemia patients with intermediate-risk cytogenetics. Issue 5 (May 2015)

• Record Type: Journal Article
• Authors: Fukuno, Kenji; Hara, Takeshi; Tsurumi, Hisashi; Shibata, Yuhei; Mabuchi, Ryoko; Nakamura, Nobuhiko; Kitagawa, Junichi; Shimizu, Masahito; Ito, Hiroyasu; Saito, Kuniaki; Moriwaki, Hisataka
• Is Part Of: Leukemia & lymphoma. Volume 56:Issue 5(2015:May)
• Page Start: 1398
• Page End: 1405
• Publication Date: 2015-05
• Subjects: Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.3109/10428194.2014.953150
• Languages: English
• ISSNs: 1042-8194

Abstract

<abstract> <title>Abstract</title> <p>The immunomodulatory effects of indoleamine 2, 3-dioxygenase (IDO) are ascribed to its ability to catalyze breakdown of the essential amino acid <sc>l</sc>-tryptophan. We applied reverse transcription-polymerase chain reaction (RT-PCR) to examine IDO mRNA expression in acute myeloid leukemia (AML) blasts, and investigated its clinical significance. We enrolled 62 patients with AML between April 2005 and March 2013. Bone marrow-derived mononuclear fractions were separated and extracted mRNA was amplified by PCR. RT-PCR showed that the bone marrow of 23 patients expressed IDO mRNA but not in 39. IDO mRNA expression did not significantly differ among cytogenetic risk profiles. The 3-year overall survival rates for patients with and without IDO mRNA expression were 39% and 74%, respectively (<italic>p</italic> &lt; 0.005). The rates for patients with intermediate-risk cytogenetics with and without IDO mRNA expression were 16% and 70%, respectively (<italic>p</italic> &lt; 0.005). The expression of IDO mRNA was associated with a poor prognosis of AML.</p> </abstract>